Advanced thyroid cancer responds to targeted therapy with sunitinib
2015-03-08
(Press-News.org) San Diego, CA--In patients with advanced thyroid cancer, sunitinib, a drug approved for treatment of several other cancers, showed significant cancer-fighting activity t, a new phase 2 clinical trial has found. Results of the single-center study will be presented Sunday at the Endocrine Society's 97th annual meeting in San Diego.
"Sunitinib can potentially be used as an effective adjunctive treatment in patients with advanced differentiated thyroid cancer," said Principal Investigator Kenneth Burman, MD, Chief of Endocrine at MedStar Washington Hospital Center, Washington, D.C.
Differentiated thyroid cancer is the most common type of cancer of the thyroid, a gland in the neck. For patients with this type of cancer, surgery and treatment with radioactive iodine to destroy the cancer cells are very effective, but in some patients, the tumor will continue to progress.
Burman and his colleagues tested the treatment effect of sunitinib in 23 patients with advanced-stage differentiated thyroid cancer who had undergone at least one course of radioactive iodine treatment. Primarily, they measured progression-free survival, the length of time that the tumor did not progress. They also measured the response of tumor growth to sunitinib using the Response Evaluation Criteria in Solid Tumors (RECIST). Patients received a starting daily dose (37.5 milligrams) of oral Sunitinib
The median progression-free survival was 241 days, or about eight months, the researchers reported.
Because this was a Phase 2 clinical trial, there was no control group. The investigators compared their results against that of the control group from a recently published study in patients with the same type of cancer who received a placebo, or "dummy" pill. Compared with these controls, Burman and his group found that the progression-free survival (PFS) with Sunitinib treatment in their study was significantly longer than without it. Further, the PFS using Sunitinib was comparable to that previously reported for Sorafenib.
According to the study abstract, 83 percent of sunitinib-treated patients benefited from treatment, with either significant shrinkage of the tumors (partial response) or slowed disease progression (stable disease). Six patients (26 percent) had a partial response to Sunitinib, and 13 (57 percent) had stable disease.
"Sunitinib is not a cure but it appears from this study that it may slow the progression of disease," Burman said.
He added that, in general, their patients tolerated the medicine fairly well, with the most commonly reported adverse events being mild or moderate.
Sunitinib is currently available for the treatment of advanced renal cell cancer and two other types of cancer under the brand name Sutent, from Pfizer, which supported this study. A targeted therapy, sunitinib works by inhibiting multiple proteins in cancer cells, limiting cancer cell growth and division.
According to Burman, sunitinib merits a larger, controlled, phase 3 trial for treatment of advanced differentiated thyroid cancer.
INFORMATION:
Founded in 1916, the Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, the Endocrine Society's membership consists of over 18,000 scientists, physicians, educators, nurses and students in 122 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Washington, DC. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.
ELSE PRESS RELEASES FROM THIS DATE:
2015-03-07
San Diego, CA-- A new testosterone nasal gel raises men's low testosterone levels to normal, with few side effects, according to the results of a phase 3 clinical trial to be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.
Last May, the U.S. Food and Drug Administration approved the medication, now called Natesto, making it the only FDA-approved nasal testosterone replacement therapy, according to the manufacturer, Trimel Pharmaceuticals.
"The unique delivery system makes this a convenient and easy-to-use, self-administered form of testosterone ...
2015-03-07
San Diego, CA-- Obstructive sleep apnea (OSA) is prevalent in obese, pregnant Asian women with gestational diabetes, even when their diabetes is controlled by diet, a new study from Thailand finds. Study results, which also connect the severity of sleep disordered breathing with higher blood glucose (sugar) levels and greater daytime sleepiness, will be presented on Saturday at the Endocrine Society's 97th annual meeting in San Diego.
In 25 women with diet-controlled gestational (pregnancy) diabetes, the researchers found a 56 percent prevalence of OSA, a sleep disorder ...
2015-03-07
San Diego, CA-- Obesity guidelines recommend an initial weight loss goal of 5 to 10% of start weight to improve health. A recent study found that patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least that level of weight loss, compared to patients on placebo who made similar lifestyle changes. Patients who achieved that weight loss showed improvements on a number of health markers, compared to those who lost less, and the patients on liraglutide showed greater improvement on ...
2015-03-07
San Diego, CA-- A new study has confirmed that transgender youth often have mental health problems and that their depression and anxiety improve greatly with recognition and treatment of gender dysphoria. The results will be presented Saturday at The Endocrine Society's 97th annual meeting in San Diego.
"Youth with gender incongruence or dysphoria need a comprehensive, multidisciplinary approach to care," said principal investigator Maja Marinkovic, MD, a pediatric endocrinologist and Medical Director of the Gender Management Clinic at Rady Children's Hospital-San Diego, ...
2015-03-07
San Diego, CA-- A fetus exposed to tobacco smoke may be at increased risk for diabetes in adulthood, a new study of adult daughters finds. The results will be presented in a poster Saturday, March 7, at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.
Women whose parents smoked during pregnancy had increased risk of diabetes mellitus independent of known risk factors, adding to the evidence that prenatal environmental chemical exposures can contribute to adult diabetes mellitus.
"From a public health perspective, reduced fetal environmental tobacco ...
2015-03-07
San Diego, CA--In older men, decreased sexual activity and desire, not erectile dysfunction, may cause serum testosterone to decline, a new study from Australia finds. The results will be presented Saturday March 7, at ENDO 2015, the annual meeting of the Endocrine Society, in San Diego.
"We found that over two years, men with declining serum concentrations of testosterone were more likely to develop a significant decrease in their sexual activity and sexual desire. In older men, decreased sexual activity and desire may be a cause - not an effect - of low circulating ...
2015-03-07
San Diego, CA--Why men have more heart disease than premenopausal women has been unclear, but a new study shows that the sex hormones testosterone and estrogen alter cardiovascular risk factors in a way that raises a man's risk of heart disease. Results of the study will be presented Saturday at the Endocrine Society's 97th annual meeting in San Diego.
Men have higher testosterone and lower estrogen levels than premenopausal women. Therefore, doctors have suspected that testosterone may promote cardiovascular disease or that estrogen may protect against it, or both, according ...
2015-03-07
San Diego, CA-- Breast cancer survivors are at increased risk of developing thyroid cancer, especially within five years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego.
"Recognition of this association between breast and thyroid cancer should prompt vigilant screening for thyroid cancer among breast cancer survivors," said lead investigator Jennifer Hong Kuo, MD, assistant professor of surgery at Columbia University, New ...
2015-03-07
San Diego, CA-- An experimental drug causes loss of weight and fat in mice, a new study has found. The study results will be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
Known as GC-1, the drug reportedly speeds up metabolism, or burning off, of fat cells.
"GC-1 dramatically increases the metabolic rate, essentially converting white fat, which stores excess calories and is associated with obesity and metabolic disease, into a fat like calorie-burning brown fat," said study author Kevin Phillips, PhD, a researcher at Houston Methodist ...
2015-03-07
San Diego, CA-- A trained scent dog accurately identified whether patients' urine samples had thyroid cancer or were benign (noncancerous) 88.2 percent of the time, according to a new study, to- be presented Friday at the Endocrine Society's 97th annual meeting in San Diego.
"Current diagnostic procedures for thyroid cancer often yield uncertain results, leading to recurrent medical procedures and a large number of thyroid surgeries performed unnecessarily," said the study's senior investigator, Donald Bodenner, MD, PhD, chief of endocrine oncology at the University of ...
LAST 30 PRESS RELEASES:
[Press-News.org] Advanced thyroid cancer responds to targeted therapy with sunitinib
